Many cannabis operators face a sudden shift in tax rules as federal rescheduling moves medical marijuana to Schedule III. However, the new federal change, Schedule III 280E tax changes for cannabis businesses, could lower tax burdens for medical-only operators and change filing strategies for mixed-use firms. This article explains those...

The AMA has urged creation of an AMA special schedule for botanical drug research to unclog research barriers. Because legal and scientific frameworks clash, clinicians and companies face confusing requirements. Therefore, the association wants a pathway like pharma studies, with rigorous trials and funding support. This article explains...